Developing cortisol modulators for a broad range of serious diseases, including endocrine, metabolic, oncologic, and psychiatric disorders
We lead the field in the research and development of selective glucocorticoid receptor (GR) antagonists.
We are committed to developing novel medications for patients suffering from diseases driven by cortisol dysregulation.
Learn MoreWe foster a diverse and collaborative environment focused on developing novel therapies that help treat people with serious unmet medical needs.
Learn MoreThis website uses cookies to help us give you the best experience when you visit. By continuing to use this website, you consent to the use of these cookies. To find out more about how we use cookies and how you can manage them go to our Cookie Notice.